Life Technologies Introduces Its Most-Efficient, Versatile Reagent for Difficult-to-Transfect Cells

Lipofectamine® 3000 demonstrates the highest transfection efficiency in the broadest spectrum of cell types with improved cell viability and reproducibility.

By | January 17, 2014

Request More Information

Life Technologies Corporation announces the launch of Lipofectamine® 3000, the company’s most efficient and versatile transfection reagent for nucleic acid delivery in the broadest spectrum of cell lines. The product increases efficiency up to 10-fold in difficult-to-transfect cells, which is key for researchers working with more biologically relevant cell models.

“Its superior transfection efficiency, coupled with the reduction of cytotoxicity-associated cell alteration, provides consistent results and more significant experiments,” said Rui Eduardo Castro, Ph.D., Av. Professor Gama Pinto, University of Lisbon, who studies the pathogenesis of human non-alcoholic liver disease (NAFLD). “This leads simply to better research.”

Working with biologically relevant cell models provides researchers with more meaningful answers to their research questions. The lack of lipid-based transfection products that efficiently transfect these cell types has challenged researchers for many years. To overcome these obstacles, Lipofectamine 3000 is designed to optimize every step in the transfection process and deliver superior performance and improved cell viability in hard-to-transfect cells researchers care about.

“The greatest benefit we’ve seen is its versatility. In some cases, it can even replace electroporation, which improves the power of experiments and the ability to make meaningful comparisons,” says Natasha Roark, Scientist, Synthetic Biology, Research and Development at Life Technologies. “Lipofectamine 3000 greatly simplifies my workflow, in part, because the viability that I’ve experienced post transfection has been much better. This allows me to get it right the first time.”

Uma Lakshmipathy, Ph.D., Principal Scientist, Cell Biology at Life Technologies, said: “Lipofectamine 3000 challenges the notion that reagent-based methods are ineffective in delivering large reprogramming vectors by enabling efficient reprogramming of skin fibroblasts with Life Technologies’ Epi5 Episomal iPSC Reprogramming Kit, therefore providing an easier and streamlined workflow for human iPSC generation.”

Request More Information

Product Details

Life Technologies Lipofectamine 3000

image of: Life Technologies Lipofectamine 3000

Superior performance into the broadest spectrum of difficult-to-transfect cell types

Request More Information

Your Request
About You
Enter text from the image above:

Add a Comment

Avatar of: You



Sign In with your LabX Media Group Passport to leave a comment

Not a member? Register Now!

LabX Media Group Passport Logo

Popular Now

  1. What Budget Cuts Might Mean for US Science
    News Analysis What Budget Cuts Might Mean for US Science

    A look at the historical effects of downsized research funding suggests that the Trump administration’s proposed budget could hit early-career scientists the hardest.  

  2. UC Berkeley Receives CRISPR Patent in Europe
    Daily News UC Berkeley Receives CRISPR Patent in Europe

    The European Patent Office will grant patent rights over the use of CRISPR in all cell types to a University of California team, contrasting with a recent decision in the U.S.

  3. Opinion: On “The Impact Factor Fallacy”
  4. Unstructured Proteins Help Tardigrades Survive Desiccation
Business Birmingham